Anandamide reduces the migration of lymphocytes to the intestine BY CB2 activation and reduces TNF-α in the target organs, protecting mice from graft-versus-host disease.

[1]  S. Gemma,et al.  Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition , 2022, Cells.

[2]  L. Newell,et al.  Acute GVHD: think before you treat. , 2021, Hematology. American Society of Hematology. Education Program.

[3]  M. Teixeira,et al.  Cannabidiol Enhances Intestinal Cannabinoid Receptor Type 2 Receptor Expression and Activation Increasing Regulatory T Cells and Reduces Murine Acute Graft-versus-Host Disease without Interfering with the Graft-versus-Leukemia Response , 2021, The Journal of Pharmacology and Experimental Therapeutics.

[4]  W. K. Simmons,et al.  The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study , 2020, Neuropsychopharmacology.

[5]  C. Hillard,et al.  Signaling Through the Type 2 Cannabinoid Receptor Regulates the Severity of Acute and Chronic Graft versus Host Disease. , 2020, Blood.

[6]  M. Arbushites,et al.  Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label, phase 2 trial. , 2020, Blood.

[7]  R. Or,et al.  Cannabinoids Reduce Inflammation but Inhibit Lymphocyte Recovery in Murine Models of Bone Marrow Transplantation , 2019, International journal of molecular sciences.

[8]  D. Bumann,et al.  Disruption of Coronin 1 Signaling in T Cells Promotes Allograft Tolerance while Maintaining Anti‐Pathogen Immunity , 2019, Immunity.

[9]  C. Marchioni,et al.  Recent advances in LC-MS/MS methods to determine endocannabinoids in biological samples: Application in neurodegenerative diseases. , 2018, Analytica chimica acta.

[10]  K. Oravecz-Wilson,et al.  Murine Models of Steroid Refractory Graft-versus-Host Disease , 2018, Scientific Reports.

[11]  D. Finn,et al.  FAAH inhibition attenuates TLR3-mediated hyperthermia, nociceptive- and anxiety-like behaviour in female rats , 2018, Behavioural Brain Research.

[12]  N. Kröger,et al.  MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. , 2018, Blood.

[13]  G. Hill,et al.  Immune regulatory cell infusion for graft-versus-host disease prevention and therapy. , 2018, Blood.

[14]  John W. Adams,et al.  APD371: a potent, highly selective, full agonist of the human CB 2 receptor with sustained analgesic effects in rodents , 2018 .

[15]  A. Wensing,et al.  Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation , 2017, The Journal of allergy and clinical immunology.

[16]  M. Teixeira,et al.  Inhibition of 5-lipoxygenase alleviates graft-versus-host disease , 2017, The Journal of experimental medicine.

[17]  Julen Oyarzabal,et al.  Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors , 2017, Front. Pharmacol..

[18]  M. Maccarrone.  Metabolism of the Endocannabinoid Anandamide: Open Questions after 25 Years , 2017, Front. Mol. Neurosci..

[19]  Yuka Kanno,et al.  Mechanisms and consequences of Jak–STAT signaling in the immune system , 2017, Nature Immunology.

[20]  S. Bonini,et al.  Inhibitor of Fatty Acid Amide Hydrolase — Learning from Tragic Failures , 2017, The New England journal of medicine.

[21]  C. Schmitt,et al.  Initiation of acute graft-versus-host disease by angiogenesis. , 2016, Blood.

[22]  R. Jenq,et al.  Role of the intestinal mucosa in acute gastrointestinal GVHD. , 2016, Hematology. American Society of Hematology. Education Program.

[23]  K. Sharkey,et al.  The Role of the Endocannabinoid System in the Brain-Gut Axis. , 2016, Gastroenterology.

[24]  B. Cravatt,et al.  Effects of fatty acid amide hydrolase (FAAH) inhibitors on working memory in rats , 2016, Psychopharmacology.

[25]  R. Mechoulam,et al.  Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  R. H. Robinson,et al.  A CB2-Selective Cannabinoid Suppresses T-Cell Activities and Increases Tregs and IL-10 , 2015, Journal of Neuroimmune Pharmacology.

[27]  S. Mineishi,et al.  State-of-the-art acute and chronic GVHD treatment , 2015, International Journal of Hematology.

[28]  D. Piomelli,et al.  Multitarget fatty acid amide hydrolase/cyclooxygenase blockade suppresses intestinal inflammation and protects against nonsteroidal anti‐inflammatory drug‐dependent gastrointestinal damage , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  H. Bradshaw,et al.  Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH). , 2014, Journal of Crohn's & colitis.

[30]  Peng Yang,et al.  Modeling, Molecular Dynamics Simulation, and Mutation Validation for Structure of Cannabinoid Receptor 2 Based on Known Crystal Structures of GPCRs , 2014, J. Chem. Inf. Model..

[31]  R. Brown, Jr.,et al.  Review article: the endocannabinoid system in liver disease, a potential therapeutic target , 2014, Alimentary pharmacology & therapeutics.

[32]  A. Lichtman,et al.  In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects , 2014, British journal of pharmacology.

[33]  I. Galve-Roperh,et al.  Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. , 2013, Progress in lipid research.

[34]  Pál Pacher,et al.  Modulating the endocannabinoid system in human health and disease – successes and failures , 2013, The FEBS journal.

[35]  L. Panlilio,et al.  Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. , 2013, Pharmacology & therapeutics.

[36]  Zhong Zhong,et al.  Cannabinoid Receptor 2 Suppresses Leukocyte Inflammatory Migration by Modulating the JNK/c-Jun/Alox5 Pathway* , 2013, The Journal of Biological Chemistry.

[37]  A. Finazzi-Agro’,et al.  Rat and human fatty acid amide hydrolases: overt similarities and hidden differences. , 2012, Biochimica et biophysica acta.

[38]  J. Wingard,et al.  First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[39]  R. Bertorelli,et al.  Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. , 2012, Pharmacological research.

[40]  T. Silva,et al.  Platelet‐activating factor receptor plays a role in the pathogenesis of graft‐versus‐host disease by regulating leukocyte recruitment, tissue injury, and lethality , 2012, Journal of leukocyte biology.

[41]  S. Grupp,et al.  Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[42]  H. Avraham,et al.  Regulation of hematopoietic stem cell trafficking and mobilization by the endocannabinoid system , 2011, Transfusion.

[43]  M. Nagarkatti,et al.  Targeting Cannabinoid Receptors as a Novel Approach in the Treatment of Graft-versus-Host Disease: Evidence from an Experimental Murine Model , 2011, Journal of Pharmacology and Experimental Therapeutics.

[44]  T. Silva,et al.  PI3Kγ controls leukocyte recruitment, tissue injury, and lethality in a model of graft‐versus‐host disease in mice , 2011, Journal of leukocyte biology.

[45]  B. Dittel,et al.  Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease , 2011, Immunologic research.

[46]  J. Dipersio,et al.  Mouse models of graft-versus-host disease: advances and limitations , 2011, Disease Models & Mechanisms.

[47]  J. Levine.  Implications of TNF-α in the pathogenesis and management of GVHD , 2011, International journal of hematology.

[48]  K. Schuebel,et al.  Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver , 2011, Proceedings of the National Academy of Sciences.

[49]  Cheng Zhu,et al.  Rolling cell adhesion. , 2010, Annual review of cell and developmental biology.

[50]  C. Constantinescu,et al.  Cannabinoids and the immune system: an overview. , 2010, Immunobiology.

[51]  D. Poetker,et al.  A comprehensive review of the adverse effects of systemic corticosteroids. , 2010, Otolaryngologic clinics of North America.

[52]  M. Teixeira,et al.  The CCL3/Macrophage Inflammatory Protein-1α–Binding Protein Evasin-1 Protects from Graft-versus-Host Disease but Does Not Modify Graft-versus-Leukemia in Mice , 2010, The Journal of Immunology.

[53]  S. Burstein,et al.  Cannabinoids, Endocannabinoids, and Related Analogs in Inflammation , 2009, The AAPS Journal.

[54]  R. Capasso,et al.  Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice , 2008, British journal of pharmacology.

[55]  Hong Zhang,et al.  Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors , 2008, Journal of Molecular Medicine.

[56]  S. O'Sullivan,et al.  Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors , 2007, British journal of pharmacology.

[57]  K. Mackie,et al.  CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. , 2007, American journal of physiology. Heart and circulatory physiology.

[58]  T. Hibi,et al.  Compound Danshen injection improves endotoxin-induced microcirculatory disturbance in rat mesentery. , 2007, World journal of gastroenterology.

[59]  T. Hibi,et al.  PROTECTIVE EFFECTS OF DIHYDROXYLPHENYL LACTIC ACID AND SALVIANOLIC ACID B ON LPS-INDUCED MESENTERIC MICROCIRCULATORY DISTURBANCE IN RATS , 2007, Shock.

[60]  W. Shlomchik,et al.  Graft-versus-host disease , 2007, Nature Reviews Immunology.

[61]  P. Massi,et al.  Cannabinoids, immune system and cytokine network. , 2006, Current pharmaceutical design.

[62]  M. Valenti,et al.  Up‐regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[63]  M. V. D. van den Brink,et al.  CCR2 is required for CD8-induced graft-versus-host disease. , 2005, Blood.

[64]  W. Jiménez.  Endocannabinoids and liver disease , 2005, Hepatology.

[65]  P. Pacher,et al.  Cannabinoids cool the intestine , 2004, Nature Medicine.

[66]  F. Khan,et al.  Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme , 2004, Bone Marrow Transplantation.

[67]  J. Serody,et al.  In vivo imaging of graft-versus-host-disease in mice. , 2004, Blood.

[68]  B. Cravatt,et al.  The endogenous cannabinoid system protects against colonic inflammation. , 2004, The Journal of clinical investigation.

[69]  R. Mechoulam,et al.  Cannabinoids and brain injury: therapeutic implications. , 2002, Trends in molecular medicine.

[70]  S Mackinnon,et al.  Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[71]  S. Narula,et al.  Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. , 2000, Molecular pharmacology.

[72]  D. Julius,et al.  Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide , 1999, Nature.

[73]  Galun,et al.  Antigen‐specific B and T cells in human/mouse radiation chimera following immunization in vivo , 1999, Immunology.

[74]  S. Mancham,et al.  Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells. , 1997, Blood.

[75]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[76]  E. Holler,et al.  Graft-versus-host disease , 2009, The Lancet.

[77]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[78]  Y. Do,et al.  Severe weight loss in 3 months after allogeneic hematopoietic SCT was associated with an increased risk of subsequent non-relapse mortality , 2015, Bone Marrow Transplantation.

[79]  Xiao Gao 高 潇,et al.  Endocannabinoids anandamide and its cannabinoid receptors in liver fibrosis after murine schistosomiasis , 2009, Journal of Huazhong University of Science and Technology [Medical Sciences].

[80]  J. Borrell,et al.  The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis. , 2009, Vitamins and hormones.

[81]  V. Di Marzo.  Endocannabinoids: synthesis and degradation. , 2008, Reviews of physiology, biochemistry and pharmacology.